Wednesday, December 08, 2021 The San Antonio Breast Cancer Symposium (December 7-10, 2021) is currently underway at the Gonzalez Convention Center in San Antonio, Texas and online.The Symposium aims to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication, and education for a broad spectrum of researchers, health professionals, and those with a special interest in breast cancer. Where and when to see CCTG studies at SABCS 2021: CCTG MA.32 – A Phase III Randomized Double-Blind Placebo-Controlled Adjuvant Trial of Metformin vs Placebo in Early Breast Cancer An oral presentation on Tuesday, December 7, 2021 CCTG MA.32, a phase III randomized double-blind placebo-controlled adjuvant trial of metformin (MET) vs placebo (PLAC) in early breast cancer (BC): Results of the primary efficacy analysis (clinical trials.gov NCT01101438) CCTG MAC.15/SWOG S1007 – A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy Plus or Minus Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx For Positive Node, Endocrine Responsive Breast Cancer. An oral presentation on Wednesday, December 8, General Session 2 Distant-disease free interval in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and her2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < or = 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): SWOG s1007 (RxPONDER) CCTG MA.9 - Poster Discussion: Thursday, December 9, 2021 Evaluation of the predicted sensitivity to endocrine therapy (SET2,3 index) and the 21-gene Breast Recurrence ScoreR assay in node-positive postmenopausal breast cancer: Results from an analysis in the SWOG S8814 trial CCTG MAC.28/NRG BR007 – Poster Session 3: Thursday, December 9, 2021 Evaluating de-escalation of breast radiation (DEBRA) following lumpectomy for breast conservative treatment of stage 1, hr+, HER2-, RS ≤18 breast cancer: NRG-BR007 a phase III trial CCTG MA.38 - Poster Session 5: Friday, December 10, 2021 Elevated plasma IL-8 predicts for reduced outcomes in CCTG MA.38, a phase 2 randomized trial of palbociclib in ER+/HER2- metastatic breast cancer patient For more information visit the SABCS website.
